Sir,

The H1-antihistamine cetirizine, a second generation piperazine derivative widely used in daily dermatology practice, is rarely the cause of cutaneous drug reaction. We present the case of a 24-year-old man with a multilocalized fixed drug eruption (FDE) following oral intake of cetirizine for his skin disease.

A 21-year-old male patient presented to department of dermatology with chief complaints of itchy dark-colored lesion over his left lower leg since 2 months. On examination there was single localized, scaly, hyperpigmented, and eczematous plaque. Diagnosis of nummular eczema was made and patient was advised topical steroid with emollients and oral cetirizine 10 mg per day to control pruritus. The following day, patient came back with multiple itchy dark color lesions associated with burning sensation over trunk, upper extremities, and buttocks. Lesions were multiple, well circumscribed, round, hyperpigmented patches with surrounding erythema \[Figure [1a](#F1){ref-type="fig"} and [b](#F1){ref-type="fig"}\]. Patient gave the history of developing these lesions immediately 1 h after taking cetirizine. Oral cavity and genitals were not involved. Patient denied any history of oral cetirizine intake and similar complaints in the past. Patient was told to stop taking cetirizine and continue with emollients. Provisional diagnosis of FDE to cetirizine and erythema multiforme was made. Use of the Naranjo Adverse Drug Reaction (ADR) Probability Scale\[[@ref1]\] indicated a probable relationship between this cutaneous adverse effect and cetirizine therapy in this patient. Histopathological examination revealed epidermal hyperplasia, spongiosis, interface vacuolar changes, pigmentary incontinence, and lymphocytes within basal layer. The dermis showed eosinophilic and neutrophilic perivascular infiltrate and extravasated red blood cells (RBCs) \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\]. Final diagnosis of FDE to cetirizine was made on basis of these findings and history. On follow-up visit, after resolution of lesions, patient denied both oral provocation test and patch testing due to the fear of having these lesions again, despite our best counselling. Patient was reassured and advised not to take cetirizine and other related piperazine derivatives in future.

![(a and b) Multiple, well-circumscribed, round, hyperpigmented patches with surrounding erythema](IDOJ-9-55-g001){#F1}

![Spongiosis, interface vacuolar changes, and pigmentary incontinence (H and E, ×40)](IDOJ-9-55-g002){#F2}

![Perivascular inflammation and extravasated red blood cells (H and E, ×40)](IDOJ-9-55-g003){#F3}

FDE is characterized by a sudden onset of annular, edematous, dusky-red macules, or plaques on the skin and/or mucous membranes, along with burning sensation and/or itching.\[[@ref2][@ref3]\] Characteristic residual hyperpigmentation will be seen after lesions subside.

Second generations H1 antihistamines have an excellent safety profile, with little or no affinity for muscarinic cholinergic receptors and are hence free from anticholinergic effects. FDE due to antihistamines is very rare, considering their extensive use worldwide for allergic rhinitis, urticaria, eczema and, other allergic disorders, and they may be under recognized. The H1-antihistaminics implicated in FDE are diphenhydramine, cyclizine, phenothiazines, loratadine, hydroxyzine, and in few cases with cetirizine and levocetirizine.\[[@ref4]\] To the best of our knowledge, there are only six case reports \[[Table 1](#T1){ref-type="table"}\] of FDE to cetirizine.\[[@ref4]\] Reactions to one preparation are likely to show similar reactions with other members of the same class.

###### 

Previous case reports of fixed drug eruption (FDE) to cetirizine
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Cetirizine, being an anti-allergic medication is rarely suspected of causing hypersensitivity reactions and FDE. Proper history, clinical examination and past history of drug reactions should be elicited and a high degree of suspicion should be kept in mind regarding possibility of reactions to antihistamines.
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